Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 Oct;34(1):52–58.

Effect of cyclophosphamide treatment on the course of Mycobacterium lepraemurium infection and development of delayed-type hypersensitivity reactions in C57B1 and BALB/c mice.

J Alexander
PMCID: PMC1537459  PMID: 373934

Abstract

Pre-treatment of Mycobacterium lepraemurium susceptible, BALB/c, and resistant, C57Bl, mice with cyclophosphamide markedly altered the development of delayed hypersensitivity during footpad infections with this organism. A tuberculin-type response demonstrated by untreated C57Bl mice was significantly intensified after week 3 in cyclophosphamide-pre-treated mice although this response had returned to normal levels by week 8. A Jones-Mote-type response demonstrated throughout experiments by untreated BALB/c mice was considerably increased in magnitude by week 3 in cyclophosphamide-pre-treated mice. By week 6 this response had become considerably protracted and was of the tuberculin-type. By week 8 however this response had started to diminish and by week 12 cyclophosphamide-treated and untreated BALB/c mice produced similar Jones-Mote-type responses when skin-tested. Cyclophosphamide pre-treatment had no effect on the growth of M. lepraemurium in C57Bl mice over 12 weeks. In BALB/c mice however cyclophosphamide-pre-treated mice demonstrated considerable resistance to infection at weeks 8 and 10 after infection but not thereafter. Whereas the magnitude of the delayed hypersensitivity response in C57Bl mice could not be correlated with resistance such a relationship could be demonstrated in BALB/c mice.

Full text

PDF
52

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Askenase P. W., Hayden B. J., Gershon R. K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med. 1975 Mar 1;141(3):697–702. doi: 10.1084/jem.141.3.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Draper P. The walls of Mycobacterium lepraemurium: chemistry and ultrastructure. J Gen Microbiol. 1971 Dec;69(3):313–324. doi: 10.1099/00221287-69-3-313. [DOI] [PubMed] [Google Scholar]
  3. HART P. D., REES R. J. Effect of macrocyclon in acute and chronic pulmonary tuberculous infection in mice as shown by viable and total bacterial counts. Br J Exp Pathol. 1960 Aug;41:414–421. [PMC free article] [PubMed] [Google Scholar]
  4. KAWAGUCHI Y. Classification of mouse leprosy. Jpn J Exp Med. 1959 Dec;29:651–663. [PubMed] [Google Scholar]
  5. Katz S. I., Parker D., Turk J. L. B-cell suppression of delayed hypersensitivity reactions. Nature. 1974 Oct 11;251(5475):550–551. doi: 10.1038/251550a0. [DOI] [PubMed] [Google Scholar]
  6. Kerckhaert J. A., Hofhuis F. M., Willers J. M. Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse. Immunology. 1977 Jun;32(6):1027–1032. [PMC free article] [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Lenzini L., Rottoli P., Rottoli L. The spectrum of human tuberculosis. Clin Exp Immunol. 1977 Feb;27(2):230–237. [PMC free article] [PubMed] [Google Scholar]
  9. Myrvang B., Feek C. M., Godal T. Antimycobacterial antibodies in sera from patients throughout the clinico-pathological disease spectrum of leprosy. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Oct;82B(5):701–706. doi: 10.1111/j.1699-0463.1974.tb00238.x. [DOI] [PubMed] [Google Scholar]
  10. Neta R., Salvin S. B. T and B lymphocytes in the regulation of delayed hypersensitivity. J Immunol. 1976 Nov;117(5 PT2):2014–2020. [PubMed] [Google Scholar]
  11. Rook G. A. Three forms of delayed skin-test response evoked by mycobacteria. Nature. 1978 Jan 5;271(5640):64–65. doi: 10.1038/271064a0. [DOI] [PubMed] [Google Scholar]
  12. Röllinghoff M., Starzinski-Powitz A., Pfizenmaier K., Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med. 1977 Feb 1;145(2):455–459. doi: 10.1084/jem.145.2.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Turk J. L., Bryceson A. D. Immunological phenomena in leprosy and related diseases. Adv Immunol. 1971;13:209–266. doi: 10.1016/s0065-2776(08)60185-6. [DOI] [PubMed] [Google Scholar]
  14. Turk J. L., Parker D. Further studies on B-lymphocyte suppression in delayed hypersensitivity, indicating a possible mechanism for Jones-Mote hypersensitivity. Immunology. 1973 Apr;24(4):751–758. [PMC free article] [PubMed] [Google Scholar]
  15. Turk J. L., Polak L., Parker D. Control mechanisms in delayed-type hypersensitivity. Br Med Bull. 1976 May;32(2):165–170. doi: 10.1093/oxfordjournals.bmb.a071350. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES